The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study
Abstract
Objective: To assess the efficacy and tolerability of canakinumab, a fully human anti–interleukin‐1β monoclonal antibody, for the treatment of acute gouty arthritis. Methods: In this 8‐week, single‐blind, double‐dummy, dose‐ranging study, patients with acute gouty arthritis whose disease was refractory to or who had contraindications to nonsteroidal antiinflammatory drugs and/or colchicine were randomized to receive a single subcutaneous dose of canakinumab (10, 25, 50, 90, or 150 mg; n = 143) or an intramuscular dose of triamcinolone acetonide (40 mg; n = 57). Patients assessed pain using a 100‐mm visual analog scale. Results: Seventy‐two hours after treatment, a statistically significant dose response was observed for canakinumab. All canakinumab doses were associated with numerically less pain than triamcinolone acetonide; thus, a dose with equivalent efficacy to triamcinolone acetonide 72 hours after treatment could not be determined. The reduction from baseline in pain intensity with canakinumab 150 mg was greater than with triamcinolone acetonide 24, 48, and 72 hours after treatment (differences of −11.5 mm [P = 0.04], −18.2 mm [P = 0.002], and −19.2 mm [P < 0.001], respectively), and 4, 5, and 7 days after treatment (all P < 0.05). Canakinumab significantly reduced the risk of recurrent flares versus triamcinolone acetonide (P ≤ 0.01 for all doses) (relative risk reduction 94% for canakinumab 150 mg versus triamcinolone acetonide). The overall incidence of adverse events was similar for canakinumab (41%) and triamcinolone acetonide (42%); most were mild or moderate in severity. Conclusion: Our findings indicate that canakinumab 150 mg provides rapid and sustained pain relief in patients with acute gouty arthritis, and significantly reduces the risk of recurrent flares compared with triamcinolone acetonide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Preliminary criteria for the classification of the acute arthritis of primary gout
Wallace, S. L., Robinson, H., Masi, A. T., Decker, J. L., Mccarty, D. J., & Yü, T. (1977) · Arthritis & Rheumatism · doi:10.1002/art.1780200320 · Cited by 1,432
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V, Conaghan, P., Gerster, J., Jacobs, J., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,407
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
A pilot study of IL-1 inhibition by anakinra in acute gout
So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727
Self-citationComparison of drug adherence rates among patients with seven different medical conditions
Briesacher, B. A., Andrade, S. E., Fouayzi, H., & Chan, K. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.437 · Cited by 587
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Wallace, K. L., Riedel, A. A., Joseph‐Ridge, N., & Wortmann, R. L. (2004) · PubMed · Cited by 426
Cited by
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24180 · Cited by 983
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41247 · Cited by 810
Metadata
- Authors
- So, A., De Meulemeester, M., Pikhlak, A., Yücel, A. E., Richard, D., Murphy, V., Arulmani, U., Sallstig, P., & Schlesinger, N.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-06-08
- Volume
- 62
- Issue
- 10
- Pages
- 3064-3076
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2084187644
- Cited by
- 315
- References
- 29
- FWCI
- 30.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study. https://app.cochat.ai/papers/10.1002/art.27600
- The paper
- So, A., De Meulemeester, M., Pikhlak, A., Yücel, A. E., Richard, D., Murphy, V., Arulmani, U., Sallstig, P., & Schlesinger, N. (2010). Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study. Arthritis & Rheumatism. https://doi.org/10.1002/art.27600
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.